{"id":"W3096278560","doi":"10.1182/blood-2020-133916","title":"Long-Term Follow-up of Ibrutinib Treatment for Rituximab-Refractory Waldenström's Macroglobulinemia: Final Analysis of the Open-Label Substudy of the Phase 3 iNNOVATETM Trial","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Rituximab; Ibrutinib; Waldenstrom macroglobulinemia; Internal medicine; Macroglobulinemia; Gastroenterology; Refractory (planetary science); Neutropenia; Progression-free survival; Phases of clinical research; Median follow-up; Surgery; Oncology; Clinical trial; Chemotherapy; Lymphoma; Leukemia; Multiple myeloma; Chronic lymphocytic leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004093865,0.0002580802,0.001232612,0.00012651,0.00008836342,0.00001767739,0.0008860981,0.0001502895,0.0001478269],"category_scores_gemma":[0.0005643792,0.0001439298,0.0005505448,0.001800922,0.0003163644,0.00005472761,0.000434075,0.0002004833,0.000002065402],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000848319,"about_ca_system_score_gemma":0.004721561,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004464805,"about_ca_topic_score_gemma":0.0001504719,"domain_scores_codex":[0.997322,0.0001449436,0.0009929913,0.0004295872,0.0007517065,0.0003587407],"domain_scores_gemma":[0.9975365,0.0003504851,0.0005318862,0.001038877,0.000415461,0.0001267754],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.386448,0.1687398,0.06213687,0.00310199,0.05698159,0.0003587986,0.009997728,0.00007008786,0.2693519,0.0004793596,0.002015834,0.04031799],"study_design_scores_gemma":[0.7531517,0.004720328,0.002984528,0.0001174653,0.009533447,0.00001618294,0.0001428508,0.00101957,0.2280663,0.000004333017,0.000119592,0.0001237546],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9948123,0.0003734065,0.00002162121,0.0005810455,0.0001746946,0.003445435,0.0004051722,0.00001206035,0.000174307],"genre_scores_gemma":[0.998909,0.00004439344,0.0001725038,0.0001124058,0.0001507575,0.0001078466,0.00007228395,0.00002986064,0.0004009402],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3667036,"threshold_uncertainty_score":0.8375847,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1374803297596642,"score_gpt":0.3988400037161458,"score_spread":0.2613596739564815,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}